Latest Safety News

Mineral Resources Limited has upgraded its lithium production guidance and reported record iron ore shipments in Q2 FY26, alongside a significant reduction in net debt and a strategic joint venture with POSCO Holdings.

Tanami Gold NL reports significant drilling progress and an 18% increase in resource tonnes at its Central Tanami Project, reinforcing its growth potential ahead of a key joint venture acquisition.

Melbana Energy’s Q4 2025 report reveals a complex quarter with drilling setbacks in Cuba due to partner payment issues, alongside significant resource upgrades offshore Australia.

Rand Mining Ltd reported a significant 96% increase in gold mined during the December 2025 quarter, driven by heightened activity at the Hornet open pit and strong processing through Evolution Mining’s Mungari plant. The company also posted improved cash flows amid ongoing exploration efforts.

Tribune Resources Ltd reported a 96% increase in gold mined at its East Kundana Joint Venture in the December 2025 quarter, alongside ongoing exploration progress in Ghana with assay results pending.

Metals X delivered near-record tin output at its Renison operation in Q4 2025, driving a doubling of EBITDA amid improved efficiencies and strong capital progress. The company also advanced its Rentails project and maintained robust cash reserves.

Paradigm Biopharmaceuticals has secured independent validation of its Phase 2 iPPS biomarker study, published in a leading rheumatology journal, reinforcing the scientific basis for its Phase 3 osteoarthritis trial.

St Barbara Limited reports strong feasibility outcomes for its New Simberi Gold Project and Nova Scotia developments, backed by significant strategic investments and regulatory approvals.

Element 25 Limited has made significant strides in advancing its Butcherbird Expansion Project in Western Australia, securing $60 million in funding and progressing key engineering and contract milestones. Simultaneously, the company moves closer to finalising financing for its US-based battery-grade manganese refinery.

Chimeric Therapeutics reports encouraging clinical progress in its CAR-T and NK cell therapy trials, alongside FDA orphan drug designation and a strategic funding boost to propel development.

Patrys Limited has acquired Reliis, gaining a promising injectable formulation of quetiapine aimed at treating delirium with a rapid FDA approval pathway. This move positions Patrys at the forefront of addressing a significant unmet medical need in critical care.

Patrys Limited has completed its acquisition of Reliis Pty Ltd, adding a promising injectable quetiapine program to its clinical pipeline and strengthening its board with two new directors.